Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain

Journal of Cataract and Refractive Surgery

Volumn 35, Issue 1, 2009, Pages 26-34

  Korenfeld, Michael S ^a   Silverstein, Steven M ^a   Cooke, David L ^a   Vogel, Roger ^a   Crockett, Robert S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; BIMATOPROST; BRIMONIDINE; DIFLUPREDNATE; DORZOLAMIDE; DUREZOL; MYDRIATIC AGENT; OCULAR ANTIINFLAMMATORY AGENT; PLACEBO; TIMOLOL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; CHEMOSIS; CHILD; CILIARY HYPEREMIA; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EDEMA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EYE INFLAMMATION; EYE PAIN; EYE SURGERY; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR FOREIGN BODY; INTRAOCULAR PRESSURE; IRITIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHOTOPHOBIA; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANTERIOR CHAMBER; CELL COUNT; DOUBLE-BLIND METHOD; EMULSIONS; FEMALE; FLUPREDNISOLONE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OPHTHALMOLOGIC SURGICAL PROCEDURES; PAIN; POSTOPERATIVE COMPLICATIONS; UVEITIS, ANTERIOR;

EID: 57849084410     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrs.2008.09.024     Document Type: Article

References (18)

1. Apple D.J., Solomon K.D., Tetz M.R., Assia E.I., Holland E.Y., Legler U.F.C., Tsai J.C., Castaneda V.E., Hoggatt J.P., and Kostick A.M.P. Posterior capsule opacification. Surv Ophthalmol 37 (1992) 73-116
2. Miyake K., Maekubo K., Miyake Y., and Nishi O. Pupillary fibrin membrane; a frequent early complication after posterior chamber lens implantation in Japan. Ophthalmology 96 (1989) 1228-1233
3. Wright P.L., Wilkinson C.P., Balyeat H.D., Popham J., and Reinke M. Angiographic cystoid macular edema after posterior chamber lens implantation. Arch Ophthalmol 106 (1988) 740-744
4. Spaide R.F., and Yannuzzi L.A. Cystoid macular edema after cataract surgery. Semin Ophthalmol 8 (1993) 121-129
5. Flach A.J. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 96 (1998) 557-634. Available at: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1298410&blobty pe=pdf Accessed September 23, 2008
6. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 5 (2005) 459-463
7. Price F. Do you welcome BAK? Weighing the toxicity risk. Optometric Management (March 2004). Available at: http://www.optometric.com/article.aspx?article=71020 Accessed September 28, 2008
8. Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye 17 (2003) 886-892
9. Yee R.W. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 18 (2007) 134-139
10. Kawashima Y, Mitsuaki K, inventors; Santen Pharmaceutical Co, Ltd., assignee. Ophthalmic compositions containing vitamin E or ester thereof as an active ingredient. US patent 5 559 157. September 24, 1996. Available at: http://www.freepatentsonline.com/5559157.html. Accessed September 23, 2008
11. Abelson M.B., and Washburn S. The downside of tear preservatives. Rev Ophthalmol May 9 (2002) 102-104. 106. Available at: http://www.revophth.com/index.asp?page=1_97.htm Accessed September 23, 2008
12. Schimmer B.P., and Parker K.L. Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's the Pharmacological Basis of Therapeutics. 10th ed. (2001), McGraw-Hill, New York, NY 1649-1677
13. Lee H.J., and Soliman M.R.I. Anti-inflammatory steroids without pituitary-adrenal suppression. Science 215 (1982) 989-991
14. Lee H.J., Cooperwood J.S., You Z., and Ko D.-H. Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch Pharm Res 25 (2002) 111-136
15. Bikowski J., Pillai R., and Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol 5 (2006) 125-130. http://findarticles.com/p/articles/mi_m0PDG/is_2_5/ai_n16085948 Accessed July 10, 2008
16. Donnenfeld E.D., Holland E.J., Stewart R.H., Gow J.A., and Grillone L.R. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation; for the Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Ophthalmology 114 (2007) 1653-1662
17. Duvall B., and Kershner R.M. Ophthalmic Medications and Pharmacology. 2nd ed. (2006), SLACK, Thorofare, NJ 53-61
18. Eisen S.A., Miller D.K., Woodward R.S., Spitznagel E., and Przybeck T.R. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150 (1990) 1881-1884